In March 2020, the FDA granted accelerated approval for the use of the PD-1 inhibitor nivolumab in combination with the CTLA-4 inhibitor ipilimumab for the treatment of patients with HCC who have previously received sorafenib treatment (FDA, 2020b). Here, CTLA4 is linked to hepatocellular carcinoma.